<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515877</url>
  </required_header>
  <id_info>
    <org_study_id>2007-005505-21</org_study_id>
    <secondary_id>2007/1297</secondary_id>
    <nct_id>NCT02515877</nct_id>
  </id_info>
  <brief_title>Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers</brief_title>
  <acronym>HPV-RX</acronym>
  <official_title>Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Phase I Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of cervical tumors depends on the stage of the disease. In advanced forms&#xD;
      (nodal and / or local extension to the vagina and / or parameters) , radiotherapy associated&#xD;
      with curietherapy , plays a major role. Until recently this association was the standard&#xD;
      treatment for advanced stage uterine cancer. With this combination, rates of local failures&#xD;
      (evolutionary prosecution and local recurrences) were 20 to 50% in stages IIb and 50-75 % for&#xD;
      stage III. More than 50% for patients with a cervical cancer locally advanced (FIGO stages II&#xD;
      / IV) . The standard treatment, external radiotherapy followed by curietherapy allows expect&#xD;
      survival rates at 5 years for approximately 30-45 %. For ten years, numerous studies have&#xD;
      evaluated the addition of concurrent chemotherapy to radiotherapy in cancer of the cervix.&#xD;
      More than 19 randomized trials have been published. A meta-analysis of these trials was&#xD;
      undertaken to assess the role of radiochemotherapy in cancers of the cervix. The first&#xD;
      meta-analysis published by the Cochrane Collaborative Group, taking into account 4580&#xD;
      patient, shows an improvement in survival, both in terms of progression free survival and&#xD;
      overall survival for patients treated with radio chemotherapy respectively 16% and 12 % (p &lt;&#xD;
      0.0001). The rate of metastasis is also decreased (p &lt; 0.0001). Survival rates were&#xD;
      significantly better when platinum salt was used ( p &lt; 0.0001 ) . However, no clinical&#xD;
      benefit of chemoradiotherapy has been demonstrated for tumors stages [1, 2] locally advanced,&#xD;
      possibly due to small number of patients. The investigators have previously shown that&#xD;
      antiviral agents used in preclinical models, Cidofovir® causes the selective&#xD;
      radiosensitization of cells infected by the papillomavirus (HPV). This trial proposes to&#xD;
      study a new concept to increase radiochemotherapy efficiency: the modulation of the&#xD;
      expression of viral oncoproteins HPV virus by an antiviral agent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>Assessed every week after inclusion up to 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Using RECIST criteria</measure>
    <time_frame>Assessed 14 weeks after inclusion</time_frame>
    <description>Using RECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy + Vistide + Chemoterapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External radiotherapy + curietherapy</intervention_name>
    <description>External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy</description>
    <arm_group_label>Radiotherapy + Vistide + Chemoterapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vistide</intervention_name>
    <description>VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg</description>
    <arm_group_label>Radiotherapy + Vistide + Chemoterapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC= 2,5 (Calvert formula)</description>
    <arm_group_label>Radiotherapy + Vistide + Chemoterapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with cervix cancer : Squamous cell carcinoma or adenocarcinoma of stage IB2&gt;&#xD;
             4 cm, II, III or IVA (International Federation of Gynecology Obstetrics, regardless of&#xD;
             pelvic lymph node status (optional surgical exploration) without paraaortic&#xD;
             metastasis.&#xD;
&#xD;
          2. Detection of the virus genome of HPV positive on the primary tumor.&#xD;
&#xD;
          3. General state ECOG performance status 0-1.&#xD;
&#xD;
          4. 18 &lt;/ = age &lt;/ = 70 years.&#xD;
&#xD;
          5. PN&gt; 2000 / mm3&#xD;
&#xD;
          6. hemoglobin&gt; 9 g/l after transfusion if necessary .&#xD;
&#xD;
          7. platelets &gt; 100 000 / mm3&#xD;
&#xD;
          8. Serum creatinine &lt;1.5 upper limit of normal.&#xD;
&#xD;
          9. Liver function tests (SGOT, SGPT, alkaline phosphatase and bilirubin) &lt;1.5 upper limit&#xD;
             of normal.&#xD;
&#xD;
         10. Life expectancy&gt; 3 months.&#xD;
&#xD;
         11. Systematic Beta HCG Dosage for premenopausal women.&#xD;
&#xD;
         12. Informed consent signed after informing the patient.&#xD;
&#xD;
         13. Proteinuria &lt;2g / L (200mg / dL) and creatinine clearance of&gt; / = 55 ml / min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other histological types of cervix tumor than those mentioned in the inclusion&#xD;
             criteria.&#xD;
&#xD;
          2. Search of viral sequences on the negative HPV tumor diagnosis.&#xD;
&#xD;
          3. History of cancer other than basal cell carcinoma.&#xD;
&#xD;
          4. Pre-treatment with radiotherapy or chemotherapy.&#xD;
&#xD;
          5. Ongoing pregnancy.&#xD;
&#xD;
          6. History or active psychiatric illness.&#xD;
&#xD;
          7. Nephropathy whatever the grade.&#xD;
&#xD;
          8. Infection scalable.&#xD;
&#xD;
          9. Active infection or other serious underlying pathology may prevent the patient&#xD;
             receiving the treatment (in particular hepatic or cardiac).&#xD;
&#xD;
         10. Inclusion in another clinical trial protocol with an experimental molecule (during the&#xD;
             study or within one month before inclusion).&#xD;
&#xD;
         11. Inability to submit to medical monitoring study for geographical, social or&#xD;
             psychological.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

